UBS initiated coverage on HAL with a buy rating and a target price of Rs 3600. HAL is a credible defence compounder in the making, it said.
UBS sells shares worth Rs 480 crore in Concord Biotech, IIFL Securities, 2 more stocks via block deals
UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, totaling Rs 480 crore. The largest sale